A5028831557- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- COVID-19 Clinical Research Studies
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Pneumonia and Respiratory Infections
- Cytomegalovirus and herpesvirus research
- Mycobacterium research and diagnosis
- Fungal Infections and Studies
- Hepatitis C virus research
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- Viral-associated cancers and disorders
- Antifungal resistance and susceptibility
- COVID-19 and healthcare impacts
- Sepsis Diagnosis and Treatment
- Polyomavirus and related diseases
- Peripheral Neuropathies and Disorders
- Herpesvirus Infections and Treatments
- Healthcare Systems and Practices
- Respiratory viral infections research
Assistance Publique – Hôpitaux de Paris
2016-2025
Hôpital Saint-Louis
2015-2025
Université Paris Cité
2012-2024
Hôpital Fernand-Widal
2015-2024
Inserm
2014-2024
Université de Bordeaux
2021-2024
Bordeaux Population Health
2021-2024
Hôpital Lariboisière
2013-2024
Sorbonne Paris Cité
2014-2024
Institut de Recherche pour le Développement
2022-2024
Background The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with major updates every two years. Guideline highlights 2019 were extended a new section focusing on drug–drug interactions and other prescribing issues in people living (PLWH). recommendations for treatment‐naïve PLWH updated four preferred regimens favouring unboosted integrase inhibitors. A two‐drug regimen dolutegravir lamivudine, three‐drug including doravirine also added to the...
Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD). However, most patients, cannot be discontinued.To evaluate the efficacy of four weekly rituximab infusions (375 mg/m(2)) after discontinuation MCD, 24 patients were enrolled onto a prospective open-label trial.At study entry, median time from MCD diagnosis was 21 months. All had stable on and dependent for 13 The CD4 cell count 270 x 10(6)/L, plasma HIV RNA less than 50 copies/mL 18...
We examined trends in the incidence of 3 AIDS-defining cancers (ADCs; Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cervical cancer) among human immunodeficiency virus (HIV)-infected patients relative to general population between 1992 2009 France, focusing on age at ADC diagnosis with controlled viral load restored immunity combination antiretroviral therapy (cART).Age- sex-standardized rates were estimated enrolled French hospital database HIV, France during 4 calendar periods...
Heavily treatment-experienced patients with good virological control could be at risk of failure on switching to a new regimen if pre-existing drug resistance is not taken into account. We examined whether genotyping based cellular HIV-1 DNA during controlled viraemia identifies mutations detected in plasma RNA treatment previous antiretroviral regimens.All 169 enrolled the Agence Nationale de Recherche sur le SIDA (ANRS) 138-intEgrase inhibitor MK_0518 Avoid Subcutaneous Injections...
We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections superinfections in onco-hematological patients with COVID-19.International, multicentre cohort study cancer COVID-19. All were included analysis at diagnosis, while only admitted least 48 h superinfections.684 (384 solid tumors 300 hematological malignancies). Co-infections documented 7.8% (54/684) 19.1% (113/590) patients, respectively. Lower respiratory tract infections most frequent infectious...
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low trough concentrations 1 3 months after the first injection, significant association no oral lead-in at month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7–29.5], P 0.01] three (OR 5.6 CI 1.3–29.7], 0.03), high BMI 1.3 1.1–1.6], 0.007).
Among patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection, salvage regimens including enfuvirtide have demonstrated sustained efficacy. Because of reluctance to use subcutaneous injections, raltegravir may be an alternative replace within a suppressive regimen. We conducted prospective, randomized, open-label trial compare the antiviral efficacy and safety switch continuing enfuvirtide.A total 170 HIV-1 infection plasma RNA levels <400 copies/mL who were...
Although the decline in cancer mortality rates with advent of combination antiretroviral therapy (cART) HIV-infected individuals can be mostly explained by a decrease cancers incidence, we looked here if improved survival after diagnosis could also contribute to this decline. Survival trends were analyzed for most frequent population followed French Hospital Database on HIV: 979 and 2,760 cases visceral non-visceral Kaposi's sarcoma (KS), 2,339 461 non-Hodgkin lymphoma (NHL) Hodgkin's (HL),...
Dexamethasone is standard of care for the treatment patients with COVID-19 requiring oxygen. The objective to assess clinical benefit adding remdesivir dexamethasone.
Tuberculosis (TB) is a leading infectious cause of death globally. It the most common opportunistic infection in people living with HIV, and their morbidity mortality. Following TB treatment, surviving individuals may be at risk for post-TB lung disease. The Sentinel Research Network (TB-SRN) provides platform coordinated observational research within International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. This prospective, cohort study will assess treatment post-treatment...
Background: The emergence of integrase strand-transfer inhibitor (INSTI) resistance-associated mutations was examined in patients with low-level viremia after switching from enfuvirtide to raltegravir the ANRS 138-Easier trial. Methods: Integrase genes plasma virus raltegravir-treated Easier trial (50–500 copies/ml) were sequenced determine INSTI mutations. Baseline viral load, baseline and nadir CD4 cell count, antiretroviral treatment, genotypic susceptibility score, level degree treatment...
Pneumocystis pneumonia is a severe opportunistic infection in immunocompromised patients caused by the unusual fungus jirovecii. Transmission airborne, with both and immunocompetent individuals acting as reservoir for fungus. Numerous reports of outbreaks renal transplant units demonstrate need valid genotyping methods to detect transmission given genotype. Here, we developed short tandem repeat (STR)-based molecular typing method P. We analyzed jirovecii genome selected six genomic STR...
Rifampicin (RIF) induces UGT1A1, an enzyme involved in raltegravir (RAL) elimination, thereby potentially lowering RAL exposure. We examined the pharmacokinetics of human immunodeficiency virus (HIV)-infected patients on RIF-based antitubercular therapy French National Agency for HIV/AIDS and Viral Hepatitis Research 12 180 Reflate Tuberculosis trial.Patients started combination with tenofovir disoproxil fumarate lamivudine after initiation RIF (10 mg/kg/day). In arm 1 (n = 21), they...
ABSTRACT Bone mineral density (BMD) declines significantly in HIV patients on antiretroviral therapy (ART). We compared the effects of intermittent versus continuous ART markers bone turnover Body Composition substudy Strategies for Management AntiRetroviral Therapy (SMART) trial and determined whether early changes predicted subsequent change BMD. For 202 participants (median age 44 years, 17% female, 74% ART) randomized to or ART, plasma inflammation were evaluated at baseline months 4 12;...